Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
DermTech, Inc. (symbol: DMTK) is a groundbreaking molecular diagnostic dermatology company dedicated to revolutionizing the diagnosis of skin conditions through innovative non-invasive testing. Located at their CLIA-licensed laboratory in La Jolla, CA, DermTech operates at the cutting edge of dermatological science.
DermTech's core technology focuses on gene expression tests that aid in the clinical diagnosis of skin cancer and other skin conditions. Their flagship product, the Pigmented Lesion Assay (PLA), allows for the analysis of skin biopsy samples using an adhesive patch. This method offers a significant advancement over traditional methods that rely on subjective visual diagnosis and invasive surgical biopsies, which are often prone to error and lead to unnecessary procedures.
The PLA test is designed to detect melanoma in clinically atypical pigmented lesions with high accuracy, providing physicians with critical, objective data to enhance patient care and reduce healthcare costs. By utilizing DermTech’s non-invasive approach, patients experience enhanced comfort and safety during the diagnostic process.
DermTech is committed to advancing the field of dermatology through continuous innovation. In addition to their focus on skin cancer, the company is developing genomic tests to diagnose inflammatory skin diseases and conditions related to aging. These efforts are aimed at providing comprehensive solutions that improve the accuracy of diagnoses and overall patient outcomes.
With a strong emphasis on scientific development and patient care, DermTech partners with various healthcare providers and institutions to expand the availability of their tests. The company generates revenue through their laboratory services, ensuring a sustainable business model while aiming for growth and expanded impact in the dermatology field.
DermTech (NASDAQ: DMTK), a leader in precision dermatology, will participate in San Diego's inaugural Five.Ten.Thirty event on April 28, 2022, celebrating Innovation Day. The event will showcase over 100 local life science and technology companies, including DermTech’s translational medicine service, DermTech Stratum™, which allows non-invasive skin sample collection to identify disease biomarkers. Recently, DermTech Stratum introduced a new test to differentiate between atopic dermatitis and psoriasis, expanding its research capabilities in inflammatory skin diseases.
DermTech (NASDAQ: DMTK) will hold a conference call on May 3, 2022, at 5:00 p.m. ET to discuss its first-quarter 2022 results. The company will also release its earnings press release prior to the call. Participants can join via U.S. toll-free number 844-467-7114 or international number 409-231-2086 using Conference ID: 6584229. DermTech aims to transform dermatology through its non-invasive skin genomics platform, focusing on early skin cancer detection and personalized treatment strategies.
CasperLabs has appointed Michael Dobak as its first Chief Marketing Officer, tasked with enhancing the brand's visibility and growth in the enterprise blockchain sector. Dobak brings over 25 years of experience from leading brands like IBM and Samsung at Ogilvy and has held key positions at BLOCKv and DermTech (NASDAQ: DMTK). His expertise is expected to accelerate business adoption of blockchain technologies, as CasperLabs marks a successful year with multiple global partnership deals.
DermTech, Inc. (NASDAQ: DMTK) has granted restricted stock units (RSUs) to a new employee, totaling 51,934 shares under its 2022 Inducement Equity Incentive Plan. The RSUs were approved on March 23, 2022, and will vest incrementally, with the first portion of 1,791 shares vesting on March 5, 2023. The remaining shares will vest 25% on the same date and the rest in quarterly installments until March 5, 2026, contingent on continued employment. DermTech specializes in non-invasive skin genomics to improve dermatological care.
DermTech, Inc. (NASDAQ: DMTK) has announced a significant advancement in melanoma detection. A study published in SKIN: The Journal of Cutaneous Medicine, led by Dr. Daniel M. Siegel, highlights the Pigmented Lesion Assay (PLA) as a cost-effective solution for assessing skin lesions. The study indicates potential annual net savings of
DermTech reported robust growth in its Q4 and full-year 2021 results, with a 42% increase in billable sample volume to approximately 11,780 and a 90% rise in assay revenue to $3.0 million for Q4. For the full year, total revenue was $11.8 million, marking a 101% increase compared to 2020. The company ended 2021 with $228.4 million in cash. However, net loss for Q4 was $26.1 million, compared to $10.7 million loss in Q4 2020. Management projects Q1 2022 assay revenue between $3.4 million and $3.8 million.
DermTech (NASDAQ: DMTK) has announced management presentations at two upcoming healthcare conferences. The Cowen 42nd Annual Health Care Conference will take place on March 8, 2022, at 12:50 p.m. Eastern Time, followed by the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 3:20 p.m. Eastern Time. Interested parties can access live webcasts and archived presentations via DermTech’s website. The company is focused on precision dermatology through non-invasive skin genomics, aiming to improve skin cancer detection and customize treatments for inflammatory diseases.
DermTech (NASDAQ: DMTK) announced the appointment of Adelle Walker as Vice President of Consumer Products, enhancing its focus on precision dermatology through a non-invasive skin genomics platform. Walker brings over 20 years of experience from Allergan and other firms, aiming to expand DermTech’s consumer reach related to skin health. The company has launched its DermTech Melanoma Test and is developing UV damage DNA risk assessment products, responding to consumer demand for detailed skin health information.
DermTech, Inc. (NASDAQ: DMTK) will release its fourth quarter and full-year 2021 financial results on March 1, 2022, after market close. A conference call to discuss these results will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can access the call by dialing (844) 467-7114 for domestic or (409) 231-2086 for international calls, using conference ID 8994008. DermTech is focused on precision dermatology through a non-invasive skin genomics platform aimed at improving early detection of skin cancers and customizing treatments.
DermTech, Inc. (NASDAQ: DMTK) announced its participation in key healthcare conferences. Management will meet with investors at the 11th Annual SVB Leerink Global Healthcare Conference on
FAQ
What is the current stock price of DermTech (DMTK)?
What is the market cap of DermTech (DMTK)?
What does DermTech, Inc. specialize in?
How does DermTech's Pigmented Lesion Assay (PLA) work?
Where is DermTech, Inc. located?
What makes DermTech's diagnostic method unique?
What other skin conditions does DermTech focus on?
How does DermTech improve patient care?
Is DermTech's technology widely available?
How does DermTech generate revenue?
What is DermTech's mission?
What recent achievements has DermTech made?
